ProtAffin Biotechnologie AG's technology is based on the interactions between pro-inflammatory proteins such as chemokines, and leucocytes and endothelial cells that drive many acute and chronic inflammatory processes such as ischemia/reperfusion injury and rheumatoid arthritis. The company's CellJammer platform uses structural bioinformatics and rational protein engineering to take a target protein agonist that naturally binds to a GAG ligand and to create an antagonist that binds with higher affinity and blocks the target protein-GAG interaction.
Impulszentrum Graz-West
Reininghausstrasse 13a
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
KalVista’s Ekterly obtains US approval as the first oral, on-demand therapy for hereditary angioedema. It will compete with established injectables.
The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.
Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.
